Jason D Fontenot
Overview
Explore the profile of Jason D Fontenot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
7514
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fong H, Mendel M, Jascur J, Najmi L, Kim K, Lew G, et al.
Stem Cells
. 2025 Jan;
PMID: 39878584
iPSCs can serve as a renewable source of a consistent edited cell product, overcoming limitations of primary cells. While feeder-free generation of clinical grade iPSC-derived CD8 T cells has been...
2.
Monteferrario D, David M, Tadi S, Zhou Y, Marchetti I, Jeanneau C, et al.
Mol Ther Methods Clin Dev
. 2024 May;
32(2):101255.
PMID: 38715734
Gene silencing without gene editing holds great potential for the development of safe therapeutic applications. Here, we describe a novel strategy to concomitantly repress multiple genes using zinc finger proteins...
3.
Ho P, Cahir-McFarland E, Fontenot J, Lodie T, Nada A, Tang Q, et al.
Sci Transl Med
. 2024 Mar;
16(738):eadm8859.
PMID: 38478632
Engineered regulatory T (T) cells have emerged as precision therapeutics aimed at inducing immune tolerance while reducing the risks associated with generalized immunosuppression. This Viewpoint highlights the opportunities and challenges...
4.
David M, Monteferrario D, Saviane G, Jeanneau C, Marchetti I, Dupont C, et al.
Mol Ther Methods Clin Dev
. 2023 Oct;
31:101111.
PMID: 37790246
B cells can differentiate into plasmablast and plasma cells, capable of producing antibodies for decades. Gene editing using zinc-finger nucleases (ZFN) enables the engineering of B cells capable of secreting...
5.
Fumagalli V, Venzin V, Di Lucia P, Moalli F, Ficht X, Ambrosi G, et al.
Sci Immunol
. 2022 Feb;
7(68):eabi6112.
PMID: 35213210
Group 1 innate lymphoid cells (ILCs), which comprise both natural killer (NK) cells and ILC1s, are important innate effectors that can also positively and negatively influence adaptive immune responses. The...
6.
Ranganath T, Simpson L, Ferreira A, Seiler C, Vendrame E, Zhao N, et al.
Front Immunol
. 2020 May;
11:714.
PMID: 32391016
Daclizumab beta is a humanized monoclonal antibody that binds to CD25 and selectively inhibits high-affinity IL-2 receptor signaling. As a former treatment for relapsing forms of multiple sclerosis (RMS), daclizumab...
7.
May-Dracka T, Arduini R, Bertolotti-Ciarlet A, Bhisetti G, Brickelmaier M, Cahir-McFarland E, et al.
Bioorg Med Chem Lett
. 2018 Apr;
28(10):1964-1971.
PMID: 29636220
Germinal center kinase-like kinase (GLK, also known as MAP4K3) has been hypothesized to have an effect on key cellular activities, including inflammatory responses. GLK is required for activation of protein...
8.
Fontenot J, Gavin M, Rudensky A
J Immunol
. 2017 Jan;
198(3):986-992.
PMID: 28115587
No abstract available.
9.
Chinen T, Kannan A, Levine A, Fan X, Klein U, Zheng Y, et al.
Nat Immunol
. 2016 Sep;
17(11):1322-1333.
PMID: 27595233
Regulatory T cells (T cells), which have abundant expression of the interleukin 2 receptor (IL-2R), are reliant on IL-2 produced by activated T cells. This feature indicates a key role...
10.
Gillard G, Saenz S, Huss D, Fontenot J
J Neuroimmunol
. 2016 May;
294:41-5.
PMID: 27138097
Innate lymphoid cells (ILCs) play an important role in immunity, inflammation, and tissue remodeling and their dysregulation is implicated in autoimmune and inflammatory disorders. We analyzed the impact of daclizumab,...